Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Forecast for the Gastric Cancer Market Growth in 2025?

There has been a swift expansion in the size of the gastric cancer market in the past few years. Projected to increase from $3.17 billion in 2024 to $3.65 billion in 2025, the market is expected to witness a compound annual growth rate (CAGR) of 15.4%. The previous growth can be credited to factors such as the swelling geriatric population, escalating healthcare consciousness, the multiplying instances of genetic mutations, the growing preference for unhealthy lifestyles, and heightened awareness about cancer.

What Is the Forecast for the Gastric Cancer Market Size Through 2029?

In the coming years, the market size for gastric cancer is anticipated to experience swift expansion. By 2029, it is predicted to reach $6.43 billion, with a Compound Annual Growth Rate (CAGR) of 15.2%. The expansion during this projected period is credited to factors such as rising obesity rates, expanding government programs, increased investment in healthcare, growing requirement for oral medications, and an upsurge in the number of cancer treatment centers. The key market trends to look out for during this period include combined chemotherapy, product diversification, robot-assisted surgeries, specialized therapies, strategic partnerships, and advanced diagnostic tools.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20797&type=smp

What are the Key Market Players in Gastric Cancer Market and How They’re Evolving?

Major companies operating in the gastric cancer market are F. Hoffmann La Roche Ltd., Merck And Co. Inc., AbbVie Inc., Sanofi S.A., Bristol Myers Squibb Company, Abbott Laboratories, Novartis AG, GlaxoSmithKline Plc, Eli Lilly and Company, Amgen Inc., Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim, Astellas Pharma Inc., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Ipsen Biopharmaceuticals Inc., Ono Pharmaceutical Co. Ltd., Samsung Biologics Co. Ltd., Celltrion Healthcare Co. Ltd., Biocon Limited, Hanmi Pharmaceuticals, Mylan N.V., Taiho Oncology Inc., Hikma Pharmaceuticals PLC, Taiho Pharmaceuticals Co. Ltd., AROG Pharmaceuticals Inc.

What Are the Primary Growth Drivers in the Gastric Cancer Market?

The growth of the gastric cancer market is anticipated to be fueled by increasing obesity incidences. Obesity, a health condition marked by an excessive accumulation of body fat and typically identified by a body mass index (BMI) of 30 or more, can lead to a range of health complications. The increase in obesity cases can be attributed to various factors like inadequate diet, absence of physical activity, sedentary lifestyles, environmental influences, and genetic factors. Excessive body fat, especially the visceral fat present around the abdomen, carries a higher risk of gastric cancer as it incites persistent inflammation and metabolic disruptions which are linked to the development of cancer, thereby leading to a surge in the need for gastric cancer treatment. For example, in March 2024, the World Health Organization, an intergovernmental organization based in Switzerland, reported that in 2022, approximately 1 in 8 people worldwide were obese, with roughly 2.5 billion adults aged 18 and over classified as overweight, which includes 890 million individuals who were obese. In the adult population, 43% were overweight and 16% were obese. In addition, 37 million children below the age of 5 were overweight and over 390 million children and young people aged between 5 and 19 were overweight, of which 160 million were obese. Consequently, the increasing obesity rates are fueling the growth of the gastric cancer market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=20797&type=smp

What Are the Leading Segments in the Global Gastric Cancer Industry?

The gastric cancer market covered in this report is segmented –

1) By Type: Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor, Other Types

2) By Diagnosis: Endoscopy, Biopsy, Imaging Tests, Exploratory Surgery, Other Diagnosis

3) By Treatment: Surgery, Radiation Therapy, Chemotherapy, Targeted Therapy, Palliative Care, Other Treatments

4) By Distribution Channel: Hospital Pharmacies, Specialty And Retail Pharmacies, Other Distribution Channels

Subsegments:

1) By Adenocarcinoma: Intestinal Type Adenocarcinoma, Diffuse Type Adenocarcinoma, Mixed Type Adenocarcinoma

2) By Lymphoma: Primary Gastric Lymphoma, Secondary Gastric Lymphoma

3) By Gastrointestinal Stromal Tumor (GIST): Primary GIST, Metastatic GIST

4) By Carcinoid Tumor: Gastric Carcinoid Type 1, Gastric Carcinoid Type 2, Gastric Carcinoid Type 3

5) By Other Types: Small Cell Carcinoma, Squamous Cell Carcinoma, Mixed Tumors

What Are the Key Market Trends in the Gastric Cancer Industry?

Top-tier companies in the gastric cancer market place a strong emphasis on the development of technologically progressive solutions such as companion diagnostic assays. These assays are employed to pinpoint patients likely to gain the most from specific therapeutic treatments, by detecting certain biomarkers. An example of this came to light in October 2024, when F. Hoffmann-La Roche Ltd., a pharmaceutical company based in Switzerland, revealed they had received approval from the U.S. Food and Drug Administration (FDA) for their product, VENTANA CLDN18 (43-14A) RxDx Assay. This was the premier immunohistochemistry (IHC) companion diagnostic used for evaluating CLDN18 protein expression in gastric and gastroesophageal junction (GEJ) adenocarcinoma. By assessing CLDN18 protein variants, this assay identifies patients suitable for targeted treatment with VYLOY (zolbetuximab), specifically the CLDN18.2 variant. Using the OptiView DAB IHC Detection Kit on the BenchMark ULTRA system, the test propels personalized healthcare forward, broadening available treatment methods for gastric and GEJ adenocarcinoma.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/gastric-cancer-global-market-report

What Is the Regional Outlook for the Gastric Cancer Market?

North America was the largest region in the gastric cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastric cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20797

This Report Delivers Insight On:

1. How big is the gastric cancer market, and how is it changing globally?

2. Who are the major companies in the gastric cancer market, and how are they performing?

3. What are the key opportunities and risks in the gastric cancer market right now?

4. Which products or customer segments are growing the most in the gastric cancer market?

5. What factors are helping or slowing down the growth of the gastric cancer market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model